Endocrine Foundations of PCOS
Expert-defined terms from the Postgraduate Certificate in PCOS Management course at Stanmore School of Business. Free to read, free to share, paired with a professional course.
Androgens are steroid hormones produced primarily by the ovarian theca cells and… #
In PCOS, excess androgen production drives clinical features such as hirsutism, acne, and alopecia. Androgen levels are measured via total and free testosterone assays, with free testosterone often reflecting bioactive hormone more accurately.
Example #
A 28‑year‑old woman with irregular menses presents with a Ferriman‑Gallwey score of 12, indicating moderate hirsutism; serum total testosterone is 85 ng/dL (reference <70 ng/dL).
Practical application #
Androgen profiling guides the selection of anti‑androgenic therapies (e.g., spironolactone, flutamide) and informs monitoring of treatment efficacy.
Challenges #
Assay variability, diurnal fluctuations, and binding protein alterations (e.g., low SHBG) can obscure true androgen status, necessitating repeat testing and careful interpretation.
Aromatase is the enzyme that converts androgens to estrogens within granulosa ce… #
Its activity influences the intra‑ovarian estrogen‑androgen balance, a key determinant of follicular development. In PCOS, reduced aromatase activity contributes to androgen excess and impaired folliculogenesis.
Example #
In vitro studies of granulosa cells from PCOS patients show a 30 % decrease in CYP19A1 mRNA expression compared with controls.
Practical application #
Aromatase modulators (e.g., letrozole) are employed off‑label to augment ovulation by increasing intra‑ovarian androgen levels, which paradoxically improves follicular responsiveness in certain PCOS phenotypes.
Challenges #
Long‑term effects on bone health and lipid metabolism remain uncertain; careful patient selection and monitoring are essential.
AMH is secreted by pre‑antral and small antral follicles and reflects the size o… #
Elevated AMH is a hallmark of PCOS, correlating with the degree of polycystic ovarian morphology (PCOM) and serving as a non‑invasive diagnostic marker.
Example #
A 22‑year‑old woman with oligomenorrhea has an AMH level of 9 ng/mL (reference 1–4 ng/mL), supporting a PCOS diagnosis.
Practical application #
AMH assists in tailoring ovulation induction protocols; higher AMH often predicts a robust response to gonadotropins, guiding dosage to avoid ovarian hyperstimulation.
Challenges #
Inter‑assay variability and lack of universally accepted cutoff values limit its standalone use; ethnicity‑specific reference ranges are still under investigation.
Adiponectin is an adipocyte‑derived hormone that enhances insulin sensitivity an… #
Women with PCOS typically exhibit reduced adiponectin levels, contributing to insulin resistance and dyslipidemia.
Example #
A cross‑sectional study found that PCOS patients had mean adiponectin concentrations 30 % lower than BMI‑matched controls.
Practical application #
Lifestyle interventions that increase adiponectin (e.g., weight loss, aerobic exercise) can improve insulin sensitivity and reduce androgen production.
Challenges #
Direct pharmacologic augmentation of adiponectin is limited; heterogeneity in assay methods hampers comparability across studies.
Adrenal androgen excess refers to overproduction of dehydroepiandrosterone sulfa… #
It accounts for up to 30 % of hyperandrogenic PCOS cases and may coexist with ovarian androgen excess.
Example #
A 35‑year‑old patient shows elevated DHEA‑S (450 µg/dL, reference <350 µg/dL) with normal ovarian androgen markers; an ACTH stimulation test confirms adrenal hyperactivity.
Practical application #
Identification of adrenal contribution directs therapy toward glucocorticoid suppression (e.g., low‑dose dexamethasone) or targeted anti‑androgen agents.
Challenges #
Chronic glucocorticoid use carries risks of weight gain, osteoporosis, and adrenal suppression; careful dose titration and monitoring are required.
Basal luteinizing hormone (LH) is measured in the early follicular phase and oft… #
An elevated LH/FSH ratio (>2) historically suggested PCOS, though its diagnostic utility has diminished with newer criteria.
Example #
A patient’s early‑follicular LH is 12 IU/L (reference 2–10 IU/L) while FSH is 5 IU/L, yielding a ratio of 2.4.
Practical application #
Basal LH can help differentiate PCOS from other causes of anovulation, such as hypothalamic amenorrhea, where LH is typically low.
Challenges #
LH levels fluctuate with stress, time of day, and assay type; reliance on a single measurement may lead to misclassification.
BMI is a simple anthropometric index (kg/m²) used to categorize weight status #
In PCOS, higher BMI correlates with greater insulin resistance, hyperandrogenism, and cardiovascular risk.
Example #
A BMI of 32 kg/m² classifies a woman as obese, and she exhibits a Homeostatic Model Assessment of Insulin Resistance (HOMA‑IR) of 4.2, indicating marked insulin resistance.
Practical application #
BMI guides therapeutic decisions; weight‑loss interventions (diet, exercise, pharmacotherapy) are first‑line for overweight/obese PCOS patients.
Challenges #
BMI does not distinguish between lean and fat mass; visceral adiposity may be high even in normal‑BMI individuals, necessitating additional measures such as waist circumference.
Cortisol, the primary glucocorticoid, is produced by the adrenal cortex in respo… #
Chronic hypercortisolemia can exacerbate insulin resistance and visceral fat accumulation, compounds often observed in PCOS.
Example #
A 30‑year‑old PCOS patient exhibits a flattened diurnal cortisol curve with elevated midnight levels, suggestive of HPA dysregulation.
Practical application #
Stress‑reduction techniques (mindfulness, CBT) and, in selected cases, low‑dose glucocorticoid antagonists may improve metabolic parameters.
Challenges #
Direct pharmacologic manipulation of cortisol is rarely indicated due to systemic effects; distinguishing primary HPA disorders from secondary changes in PCOS can be complex.
DHT is a potent androgen derived from testosterone via 5α‑reductase #
It binds androgen receptors with higher affinity, driving cutaneous manifestations such as hirsutism and acne.
Example #
Serum DHT measurement shows 450 pg/mL (reference <250 pg/mL) in a woman with severe hirsutism despite normal total testosterone.
Practical application #
5α‑reductase inhibitors (e.g., finasteride) can reduce DHT levels, alleviating androgenic skin symptoms.
Challenges #
Potential teratogenicity limits use in women of reproductive age; long‑term safety data are limited.
DHEA‑S is the sulfated form of dehydroepiandrosterone, predominantly secreted by… #
Elevated DHEA‑S is a marker of adrenal androgen excess and may indicate a specific PCOS phenotype with higher metabolic risk.
Example #
A 27‑year‑old woman has a DHEA‑S of 420 µg/dL (reference <350 µg/dL) and displays insulin resistance (HOMA‑IR = 3.8).
Practical application #
DHEA‑S levels help tailor therapeutic strategies; patients with marked adrenal contribution may benefit from low‑dose glucocorticoids or adrenal‑targeted anti‑androgens.
Challenges #
DHEA‑S lacks specificity for PCOS, as levels rise with age and in adrenal disorders; interpretation must be contextual.
Estradiol (E2) is the principal estrogen produced by granulosa cells after aroma… #
In PCOS, estradiol may be normal or modestly elevated, but its pulsatile secretion pattern is often disrupted, affecting the feedback regulation of LH and FSH.
Example #
A patient’s mid‑cycle estradiol peaks at 150 pg/mL, lower than the expected >300 pg/mL, reflecting impaired follicular maturation.
Practical application #
Monitoring estradiol assists in timing ovulation induction and assessing response to gonadotropins.
Challenges #
Estradiol assays vary in sensitivity; cycle‑phase timing must be strictly standardized to avoid misinterpretation.
FSH is a pituitary‑derived gonadotropin essential for recruitment and growth of… #
In PCOS, basal FSH is often normal or low, contributing to arrested follicular development and anovulation.
Example #
Early‑follicular FSH of 4 IU/L (reference 4–10 IU/L) combined with elevated LH suggests a disrupted LH/FSH ratio.
Practical application #
Exogenous FSH is a cornerstone of controlled ovarian stimulation for assisted reproduction in PCOS patients.
Challenges #
Excessive FSH dosing can precipitate ovarian hyperstimulation syndrome (OHSS); individualized protocols are required.
Gonadotropin‑releasing hormone (GnRH) is secreted by hypothalamic neurons in a p… #
In PCOS, increased GnRH pulse frequency favors LH dominance, perpetuating androgen excess.
Example #
Women with PCOS exhibit GnRH pulse intervals of 30–45 minutes versus 60–90 minutes in normal cycles.
Practical application #
Pulsatile GnRH therapy can normalize LH/FSH balance and restore ovulation in selected cases.
Challenges #
Continuous GnRH analogues suppress the axis, useful for hyperandrogenic symptom control but requiring careful re‑initiation for fertility.
Hyperandrogenism denotes elevated androgen levels, manifesting clinically as hir… #
It is a core diagnostic criterion for PCOS.
Example #
A patient meets Rotterdam criteria with oligo‑ovulation and biochemical hyperandrogenism (total testosterone = 95 ng/dL).
Practical application #
Quantifying hyperandrogenism directs anti‑androgenic treatment and monitors therapeutic response.
Challenges #
Mild hyperandrogenism may be missed without sensitive assays; ethnic variations in hair growth patterns can confound clinical assessment.
IR describes a diminished cellular response to insulin, leading to compensatory… #
In PCOS, IR is present in up to 70 % of patients, independent of obesity, and drives ovarian androgen production via theca‑cell stimulation.
Example #
HOMA‑IR calculated as fasting insulin × fasting glucose/22.5 yields a value of 4.5 (reference <2.5), indicating significant IR.
Practical application #
Metformin and thiazolidinediones improve insulin sensitivity, reduce androgen levels, and restore ovulatory cycles.
Challenges #
Not all patients tolerate metformin; lifestyle modification is essential but often insufficient alone.
IGF‑1 amplifies the actions of insulin on ovarian theca cells, enhancing steroid… #
Elevated IGF‑1 levels or reduced IGF‑binding protein‑1 (IGFBP‑1) are observed in PCOS, contributing to hyperandrogenism.
Example #
Serum IGF‑1 of 250 ng/mL (reference 100–200 ng/mL) accompanies high free testosterone in a PCOS patient.
Practical application #
Lifestyle and pharmacologic interventions that lower IGF‑1 (e.g., weight loss, metformin) can attenuate androgen synthesis.
Challenges #
Direct IGF‑1 targeting is limited by systemic effects on growth and metabolism.
LH is a pituitary gonadotropin that stimulates theca cells to produce androgens… #
In PCOS, basal LH is often elevated, reflecting altered GnRH pulsatility.
Example #
Basal LH of 13 IU/L exceeds the upper limit of normal, contributing to excessive androgen output.
Practical application #
Exogenous LH (or hCG) is used to induce final oocyte maturation in assisted reproductive protocols.
Challenges #
Excessive LH can exacerbate androgen excess; careful dosing is needed to avoid OHSS.
Metformin is an oral biguanide that improves insulin sensitivity, reduces hepati… #
It is a first‑line pharmacologic agent for metabolic and reproductive aspects of PCOS.
Example #
After three months of metformin 1500 mg/day, a patient’s menstrual cycles normalize from 8‑month amenorrhea to 28‑day cycles.
Practical application #
Metformin facilitates weight loss, improves ovulatory rates, and may lower the risk of gestational diabetes in pregnant PCOS patients.
Challenges #
Gastrointestinal side effects limit adherence; renal function must be monitored to avoid lactic acidosis.
Irregular menstrual cycles, ranging from oligomenorrhea (>35‑day intervals) to a… #
They are a clinical diagnostic component and a primary concern for fertility.
Example #
A patient reports 48‑day cycles for six consecutive months, confirming oligomenorrhea.
Practical application #
Cycle tracking combined with hormonal assays informs the need for ovulation induction.
Challenges #
Cycle variability can be influenced by stress, weight changes, and concurrent endocrine disorders, complicating diagnosis.
MiRNAs are small non‑coding RNAs that modulate gene expression post‑transcriptio… #
Specific miRNA signatures are altered in PCOS, affecting insulin signaling, steroidogenesis, and inflammation.
Example #
miR‑93 is up‑regulated in granulosa cells of PCOS patients, suppressing GLUT4 expression and worsening insulin resistance.
Practical application #
miRNA profiling may aid in phenotyping PCOS and identifying novel therapeutic targets.
Challenges #
Clinical translation is limited by assay standardization, tissue accessibility, and inter‑individual variability.
Obesity, particularly central (visceral) adiposity, intensifies insulin resistan… #
It is both a contributor to and a consequence of endocrine dysfunction.
Example #
A waist circumference of 102 cm in a PCOS patient predicts higher likelihood of dyslipidemia and hypertension.
Practical application #
Structured weight‑loss programs (dietary caloric restriction, exercise, behavioral therapy) are integral to PCOS management.
Challenges #
Weight regain is common; bariatric surgery may be considered for severe obesity but carries operative risks and requires lifelong follow‑up.
Theca cells surround developing follicles and, under LH influence, convert chole… #
In PCOS, theca cells are hyperresponsive, producing excess androgens even with normal LH levels.
Example #
In vitro culture of PCOS theca cells shows a 2‑fold increase in testosterone output compared with controls.
Practical application #
Targeting theca‑cell hyperactivity with insulin‑sensitizers or anti‑androgens reduces androgen excess.
Challenges #
Direct theca‑cell therapies are lacking; systemic agents may have off‑target effects.
PCOM is defined by trans‑vaginal ultrasound as ≥12 antral follicles (2–9 mm) in… #
It is a structural component of the Rotterdam diagnostic criteria.
Example #
An ultrasound reveals 16 peripheral follicles in the right ovary, confirming PCOM.
Practical application #
PCOM assists in diagnosis when biochemical or clinical signs are equivocal and guides monitoring of follicular response during ovulation induction.
Challenges #
Ultrasound resolution varies; age‑related declines in follicle number may lead to false‑negative findings in older women.
Progesterone is secreted by the corpus luteum post‑ovulation, preparing the endo… #
In PCOS, chronic anovulation leads to progesterone deficiency, increasing risk of endometrial hyperplasia.
Example #
Serum progesterone measured in the luteal phase is <1 ng/mL, confirming lack of ovulation.
Practical application #
Progestin therapy (cyclic oral contraceptives) protects the endometrium and regulates menstrual bleeding.
Challenges #
Progestin side effects (weight gain, mood changes) may limit adherence; appropriate dosing must balance efficacy and tolerability.
Elevated prolactin can mimic PCOS symptoms (amenorrhea, infertility) #
While not a primary feature of PCOS, prolactin levels must be screened to exclude secondary causes.
Example #
A patient’s serum prolactin is 45 ng/mL (reference <25 ng/mL); MRI reveals a microadenoma.
Practical application #
Dopamine agonists (cabergoline) normalize prolactin, restore ovulation, and differentiate true PCOS from prolactinoma‑related anovulation.
Challenges #
Misdiagnosis may lead to inappropriate PCOS treatment; pituitary imaging and endocrine work‑up are essential.
SHBG is a hepatic glycoprotein that binds testosterone and estradiol, reducing t… #
Insulin resistance suppresses SHBG production, increasing free androgen levels in PCOS.
Example #
SHBG of 20 nmol/L (reference 30–120 nmol/L) contributes to elevated free testosterone despite normal total testosterone.
Practical application #
Improving insulin sensitivity (e.g., metformin, weight loss) raises SHBG, thereby lowering free androgen activity.
Challenges #
Genetic polymorphisms affect SHBG levels; assay variability can obscure trends.
Steroidogenesis encompasses the enzymatic conversion of cholesterol to steroid h… #
Dysregulated steroidogenic enzyme activity (e.g., CYP17A1, 3β‑HSD) underlies androgen excess in PCOS.
Example #
Increased CYP17A1 expression in theca cells amplifies androgen synthesis.
Practical application #
Inhibitors of steroidogenic enzymes (e.g., ketoconazole, though off‑label) may reduce androgen production in refractory cases.
Challenges #
Enzyme inhibitors often have hepatic toxicity; specificity for ovarian tissue is lacking.
TSH regulates thyroid hormone production #
Subclinical hypothyroidism can coexist with PCOS, exacerbating dyslipidemia and weight gain. Routine TSH screening is recommended in PCOS work‑up.
Example #
A TSH of 5.2 µIU/mL (reference 0.4–4.0 µIU/mL) prompts levothyroxine initiation.
Practical application #
Treating hypothyroidism may improve menstrual regularity and metabolic parameters.
Challenges #
Distinguishing the contribution of thyroid dysfunction from PCOS‑related endocrine abnormalities requires comprehensive evaluation.
Visceral fat, located intra‑abdominally, is metabolically active, secreting adip… #
PCOS patients often exhibit disproportionate visceral fat even with normal BMI.
Example #
MRI quantifies visceral fat area of 150 cm², exceeding the gender‑specific threshold.
Practical application #
Targeted aerobic exercise reduces visceral fat more effectively than diet alone, improving insulin sensitivity.
Challenges #
Imaging modalities are costly; surrogate measures (waist circumference) may lack precision.
Effective weight management is central to PCOS care, aiming to reduce insulin re… #
Approaches range from lifestyle modification to pharmacologic agents (e.g., orlistat) and bariatric procedures for severe obesity.
Example #
A 10 % body weight reduction yields a 20 % decrease in free testosterone and restoration of ovulation in many patients.
Practical application #
Multidisciplinary programs integrating dietitians, exercise physiologists, and psychologists improve long‑term adherence.
Challenges #
High relapse rates; socioeconomic barriers limit access to comprehensive programs.
Xenoestrogens are synthetic or natural compounds that mimic estrogenic activity,… #
Exposure to bisphenol A (BPA) has been linked to worsened insulin resistance and hyperandrogenism in PCOS.
Example #
Urinary BPA concentrations correlate with higher LH/FSH ratios in a cohort of PCOS women.
Practical application #
Counseling on reducing plastic use, opting for BPA‑free containers, and limiting phytoestrogen‑rich supplements may mitigate exposure.
Challenges #
Ubiquitous presence makes complete avoidance difficult; epidemiologic data are associative, not causative.
While primarily relevant to male reproductive health, Y‑chromosome microdeletion… #
While primarily relevant to male reproductive health, Y‑chromosome microdeletions can be considered in couples where the male partner presents infertility, influencing overall PCOS management strategies.
Example #
AZFc microdeletion identified in a male partner prompts referral for assisted reproductive techniques.
Practical application #
Understanding male factor contributions ensures comprehensive couple‑based counseling and treatment planning.
Challenges #
Limited direct impact on female endocrine pathology; requires coordinated interdisciplinary care.
Zinc is a trace mineral involved in insulin synthesis, antioxidant defense, and… #
Deficiency may exacerbate insulin resistance and affect ovarian function.
Example #
Serum zinc of 55 µg/dL (reference 70–120 µg/dL) in a PCOS patient correlates with elevated HOMA‑IR.
Practical application #
Zinc supplementation (30 mg elemental zinc daily) can modestly improve insulin sensitivity and menstrual regularity.
Challenges #
Excess zinc interferes with copper absorption; dosing must be balanced and monitored.